Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) toestablish an eff ective, eff icient, integrated pharmacy benefits program for theMilitary Health System (MHS) which includes the purchase pharmaceuticalagents. The law and implementing regulation (32 CFR Section 199.21) describethe process by which the DoD Pharmacy and Therapeutics (P&T) Committee willconsider the relative clinical eff ectiveness and relative cost eff ectiveness ofpharmaceutical agents in a therapeutic class in recommending the selection ofagents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic CoreFormulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior tothe scheduled P&T Committee meeting, a Request for Quotation (RFQ) forpharmaceutical agents within Drug Classes identified for placement on the UFhas been issued to obtain quotes from industry. The Defense Health Agency mayaward Uniform Formulary Blanket Purchase Agreements (UF BPA) and theUniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: August 2023: The following drug classes/subclass will be reviewed:

a. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Central Precocious Puberty Agents
Fensolvi
Lupron Depot-Ped

b. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Endometriosis /Fibroids Agent
Lupron Depot 3.75mg & 11.25mg 
Myfembree
Oriahnn
Orilissa

c. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Prostate Cancer Agents
Camcevi
Eligard
Firmagon
Lupron Depot 7.5mg, 22.5mg, 30mg, & 45mg
Leuprolide Acetate Injection Depot 22.5mg
Orgovyx

d. White Blood Cell Stimulants Subclass: Filgrastim
Granix
Neupogen
Nivestym
Releuko
Zarxio

e. White Blood Cell Stimulants Subclass: Pegfilgrastim
Fulphila
Fylnetra
Neulasta
Neulasta OnPro
Nyvepria
Stimufend
Udenyca
Ziextenzo

The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQHT9402-23-Q-9301.

Pre-proposal teleconference is on May 10, 2023, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.